Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America Meningococcal Vaccines Market

ID: MRFR/MED/51389-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026

South America Meningococcal Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines, Conjugate Vaccines), By Age Group (Infants, Children, Adolescents, Adults), By Administration Route (Intramuscular, Subcutaneous, Oral), By Distribution Channel (Hospitals, Clinics, Pharmacies) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America Meningococcal Vaccines Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Vaccination Programs
      2. 4.1.2 Travel Vaccination
      3. 4.1.3 Routine Immunization
      4. 4.1.4 Outbreak Response
      5. 4.1.5 Healthcare Settings
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Hospitals
      2. 4.2.2 Clinics
      3. 4.2.3 Pharmacies
      4. 4.2.4 Public Health Organizations
      5. 4.2.5 Research Institutions
    3. 4.3 Healthcare, BY Type of Vaccine (USD Million)
      1. 4.3.1 Meningococcal A
      2. 4.3.2 Meningococcal B
      3. 4.3.3 Meningococcal C
      4. 4.3.4 Meningococcal ACWY
      5. 4.3.5 Meningococcal Y
    4. 4.4 Healthcare, BY Age Group (USD Million)
      1. 4.4.1 Infants
      2. 4.4.2 Children
      3. 4.4.3 Adolescents
      4. 4.4.4 Adults
      5. 4.4.5 Elderly
    5. 4.5 Healthcare, BY Distribution Channel (USD Million)
      1. 4.5.1 Direct Sales
      2. 4.5.2 Distributors
      3. 4.5.3 Online Sales
      4. 4.5.4 Pharmacies
      5. 4.5.5 Healthcare Providers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Pfizer (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 GlaxoSmithKline (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Sanofi (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co. (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Novartis (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Baxter International (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Serum Institute of India (IN)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Biological E. Limited (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY END USE
    4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY TYPE OF VACCINE
    5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
    6. 6.6 SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TYPE OF VACCINE, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TYPE OF VACCINE, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY TYPE OF VACCINE, 2026-2035 (USD Million)
      4. 7.2.4 BY AGE GROUP, 2026-2035 (USD Million)
      5. 7.2.5 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America Healthcare Market Segmentation

Healthcare By Application (USD Million, 2026-2035)

  • Vaccination Programs
  • Travel Vaccination
  • Routine Immunization
  • Outbreak Response
  • Healthcare Settings

Healthcare By End Use (USD Million, 2026-2035)

  • Hospitals
  • Clinics
  • Pharmacies
  • Public Health Organizations
  • Research Institutions

Healthcare By Type of Vaccine (USD Million, 2026-2035)

  • Meningococcal A
  • Meningococcal B
  • Meningococcal C
  • Meningococcal ACWY
  • Meningococcal Y

Healthcare By Age Group (USD Million, 2026-2035)

  • Infants
  • Children
  • Adolescents
  • Adults
  • Elderly

Healthcare By Distribution Channel (USD Million, 2026-2035)

  • Direct Sales
  • Distributors
  • Online Sales
  • Pharmacies
  • Healthcare Providers

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions